Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mindset Pharma Inc (OP: MSSTF )

N/A UNCHANGED
Last Price Updated: 3:55 PM EDT, Oct 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.5381
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic... 
Via Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga

Performance

More News

Read More
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Via Benzinga
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
Via Benzinga
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Via Benzinga
UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression
Via Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Via Benzinga
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
Via Benzinga
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Via Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
Via Benzinga
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Via Benzinga
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
Via Benzinga
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
From PharmAla Biotech
Via GlobeNewswire
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
Via Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
Via Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Via Benzinga
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.